Characteristics of cytotoxic antibodies against neuraminidase-treated lymphocytes in man.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000302:isolation & purification; D000918:Antibody Specificity; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D003165:Complement System Proteins; D005690:Galactose / Q000494:pharmacology; D006384:Hemagglutination; D006801:Humans; D007163:Immunosorbent Techniques; D066298:In Vitro Techniques; D007231:Infant, Newborn; D007252:Influenza Vaccines / Q000494:pharmacology; D007785:Lactose / Q000494:pharmacology; D008214:Lymphocytes / Q000276:immunology*; D008875:Middle Aged; D009439:Neuraminidase / Q000494:pharmacology*
D000906:Antibodies; D007252:Influenza Vaccines; D003165:Complement System Proteins; D009439:Neuraminidase; D007785:Lactose; D005690:Galactose